Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19 (STEPCO)

Schön Klinik Berchtesgadener Land

Status: Completed

Conditions: Quality of Life; SARS-CoV Infection; Covid19; Pulmonary Rehabilitation

Treatments: Other: pulmonary rehabilitation

Study type: Observational

Funder types: Other

Identifiers

NCT04649918

COVID-Rehab

Details and patient eligibility

About

As a direct consequence of the COVID-19 pandemic, it is assumed that the number of patients with COVID-19-related disabilities will increase significantly. Patients with mild, severe, and critical forms of the disease show long-term sequelae in different systems (respiratory, muscular, psychological, cognitive etc.).

Persistent dyspnea is a frequently described symptom after the acute phase of the disease. Coupled with reduced oxygen saturation, an increased risk of developing lung fibrosis has been observed. Specialized rehabilitation medicine (e.g. pulmonary rehabilitation) might counteract these long-term consequences and therefore seems to be a promising approach to treat long-term COVID-19 consequences.

Further, there is scarce evidence about COVID-19 specific rehabilitation contents. It was suggested to use treatment regimes in analogy to patients with idiopathic pulmonary fibrosis.

There is evidence that pulmonary rehabilitation improves physical performance, quality of life and reduces anxiety and depression symptoms in patients with idiopathic pulmonary fibrosis and other chronic respiratory diseases.

Since impairments related to idiopathic pulmonary fibrosis also play an important role in COVID-19, the aim of this study is to evaluate the short and medium-term effects of a standardized 3-week pulmonary rehabilitation program. The results will be analyzed within the two cohorts (mild/moderate and severe/critical COVID 19) as well as between the two cohorts for the primary outcome. Furthermore, the effects of pulmonary rehabilitation will be compared with a retrospective cohort of idiopathic pulmonary fibrosis.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Post-acute phase COVID-19 patients with mild, moderate, severe or critical course
• written informed consent

Exclusion criteria

• patients who are unable to walk

Trial design

50 participants in 2 patient groups

mild to moderate COVID 19

Description:

patients post-acute mild to moderate COVID 19

Treatment:

Other: pulmonary rehabilitation

severe to critical COVID 19

Description:

patients post-acute severe to critical COVID 19

Treatment:

Other: pulmonary rehabilitation